Tesamorelin
10mg
A peptide that works with your body's own hormone system — signaling the pituitary gland to release growth hormone the natural way, in pulses, rather than flooding the body with it directly. Research has examined its role in body composition, visceral fat reduction, metabolic health, and IGF-1 levels.
The pituitary's
natural rhythm.
Restored.
A synthetic analogue of GHRH that tells the pituitary to produce growth hormone the way it was designed to — in natural pulses, with the body's own feedback systems intact. Studied for its effects on body composition, metabolic health, and the GH/IGF-1 axis.
Falutz et al. NEJM 2007 · Stanley et al. NEJM 2012 · PLOS One 2017. All data from peer-reviewed literature. For Research Use Only — Not for Human Consumption. Not the FDA-approved drug EGRIFTA®.
Manufactured in US
US-formulated & filled
Endotoxin Tested
<0.05 EU/mL verified
Independently Tested
Horizon Analytical · 6-panel COA
Same Day Shipping
Order by 3PM PST
Know what
you're buying.
Tesamorelin has an approved pharmaceutical form. What Trident Labs supplies is the research-grade peptide — not the drug. The distinction matters.
EGRIFTA® / EGRIFTA SV® / EGRIFTA WR™
FDA-approved pharmaceutical injectable drugs for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Approved 2010 — EGRIFTA WR™ (newest formulation) approved March 2025. Manufactured by Theratechnologies Inc.
Trident Labs — Tesamorelin (Research Grade)
Identical-sequence synthetic peptide supplied exclusively for in vitro laboratory research. Not formulated as a pharmaceutical injection. Not approved for any therapeutic use. Not the drug EGRIFTA®. For Research Use Only — Not for Human Consumption.
By purchasing, the buyer represents they are a qualified researcher using this compound solely for lawful in vitro laboratory research. Not a drug, dietary supplement, food, or medical device under US regulations.
1
modification.
Complete protection.
Native GHRH is destroyed within minutes. A single chemical addition to its N-terminus blocks the enzyme that degrades it — tightening receptor binding and enabling meaningful research concentrations in cell-based assays.
H₂N–Tyr–Ala–Asp–Ala–Ile–Phe–Thr–Asn–Ser–...
DPP-IV cleaves Tyr¹–Ala² within minutes → inactive fragment
Hex–Tyr–Ala–Asp–Ala–Ile–Phe–Thr–Asn–Ser–...
DPP-IV sterically blocked · receptor affinity enhanced · stability extended
44
Identical residues to GHRH
1
Chemical modification
DPP4
Enzyme fully blocked
↑
Tighter receptor binding
PMID: 16052083 · FDA EGRIFTA prescribing information 2025
How tesamorelin
works in context.
Tesamorelin enters at the pituitary — not the hypothalamus. This single point of action preserves every downstream feedback loop that keeps GH physiology in balance.
Hypothalamus
Releases native GHRH — degraded by DPP-IV within minutes
Tesamorelin
DPP-IV resistant — reaches pituitary intact · activates GHRH-R with high affinity
Anterior Pituitary
GHRH-R → Gαs → cAMP → PKA → Ca²⁺ → pulsatile GH release
Liver · Muscle · VAT
GH → hepatic IGF-1 · lean mass · lipolysis in visceral adipose tissue
Somatostatin + IGF-1
Dual feedback brake preserved — prevents GH excess · no insulin resistance
Falutz et al. NEJM 2007 · PLOS One PMC5472315. GH axis schematic — research context only.
The numbers behind
the research interest.
Two landmark NEJM publications — the strongest clinical evidence base of any peptide in our research catalogue. These findings shaped how the GH axis is studied.
15–18%
Visceral Adipose Tissue Reduction
CT-measured VAT reduction over 26 weeks vs placebo. Triglycerides also significantly reduced. No adverse change in insulin sensitivity.
Falutz J et al., NEJM 2007;357(23):2349. n=412
0
Insulin Resistance Induced
No change in fasting glucose, OGTT, or HbA1c — even in Type 2 diabetic patients. Intact somatostatin + IGF-1 feedback prevents GH excess.
Koutkia P et al., PLOS One 2017;12(6):e0179538
412
Phase III Patients
Randomized placebo-controlled Phase III RCT. Tesamorelin 2 mg/day vs placebo, 26-week primary endpoint, 52-week extension.
Falutz 2007 — basis for 2010 FDA approval of EGRIFTA®
2010
FDA Approval Year
EGRIFTA® — only FDA-approved GHRH analogue in the US
IGF-1
Cognitive Endpoint Marker
IGF-1 levels correlated with cognitive preservation (Stanley NEJM 2012)
Two sides of
the same cascade.
The activation that produces GH, and the brake that keeps it physiological. Understanding both is essential for clean GH axis research design.
Activation cascade
GHRH-R Binding → Gαs Activation
Tesamorelin binds GHRH receptors on pituitary somatotrophs. The hexenoyl modification creates tighter receptor engagement than native GHRH — stronger activation from the initial binding event (PMID: 16052083).
cAMP → PKA → Ca²⁺ → GH Exocytosis
Gαs → adenylate cyclase → ↑cAMP → PKA → voltage-gated Ca²⁺ channels open → pre-formed GH granules release. Measurable via GH RIA/ELISA in conditioned media from pituitary cell cultures (GC cells, primary somatotrophs).
GH → Liver → IGF-1 → Target Tissues
GH acts on hepatocyte GH receptors via JAK2/STAT5 → IGF-1 gene transcription. IGF-1 mediates lipolysis in visceral adipocytes (HSL activation), lean mass anabolism in muscle, and glucose metabolism modulation.
The physiological brake — why this matters
Somatostatin Brake — Intact
Tesamorelin acts at the pituitary — not the hypothalamus. The hypothalamus continues releasing somatostatin between GH pulses, shutting down secretion normally. This is why GH remains pulsatile rather than continuous — the defining mechanistic difference from exogenous GH.
IGF-1 Negative Feedback — Intact
Rising IGF-1 feeds back to suppress further GH release — the same mechanism that prevents excess in healthy physiology. IGF-1 stays within normal physiological range even with chronic tesamorelin administration. This is why insulin resistance was not observed even in T2D patients (PLOS One 2017).
Research Implication — Physiological GH Model
The dual-brake preservation makes tesamorelin the preferred model for studying physiological GH secretion patterns vs. the pharmacological flat-line of exogenous GH. For in vitro work, this translates to studies of pulsatile GH receptor activation kinetics and downstream IGF-1 quantification in physiologically relevant concentration ranges.
Full specification.
Molecular and analytical data from peer-reviewed literature and Trident Labs batch records.
Long-term
−20°C
Lyophilized, sealed. Stable 24 months. Avoid frost-free freezers.
In solution
4°C
7 days max. Single-use aliquots. Do not refreeze after reconstitution.
Solvent
Sterile H₂O
Reconstitute in sterile water. 0.5–1 mg/mL stock. Avoid bacteriostatic water.
Avoid
Oxidants
Met residue susceptible. Use amber vials. Protect from light post-reconstitution.
For Research Use Only — Not for Human Consumption. Not EGRIFTA® or any approved drug. Supplied exclusively for in vitro laboratory research by qualified researchers.
| Common Name | Tesamorelin / TH9507 / GRF(1–44) analogue |
| CAS Number | 218949-48-9 |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | 5,135.9 Da (free base) |
| Structure | 44-AA GHRH(1–44) + trans-3-hexenoyl N-terminal conjugate |
| Primary Target | GHRH receptor (GHRHR) — pituitary somatotroph Gαs-coupled GPCR |
| Signaling | GHRHR → Gαs → ↑cAMP → PKA → Ca²⁺ → GH exocytosis |
| GH Pattern | Pulsatile — somatostatin and IGF-1 feedback intact |
| Plasma Tmax | ~0.15 hr · AUC 634.6 pg·h/mL |
| Form | Lyophilized powder · sealed glass vial |
| Purity | ≥99% HPLC · Mass Spec verified · 6-panel COA · Horizon Analytical |
| Endotoxin | <0.05 EU/mL · LAL-tested · Horizon Analytical |
| Solubility | Sterile water, PBS · 0.5–1 mg/mL working stock |
| Regulatory | RUONot EGRIFTA® — In Vitro Research Use Only |
Indexed research on Tesamorelin.
Independent peer-reviewed studies. Not Trident Labs claims. For Research Use Only.
Effects of Tesamorelin on Visceral Adiposity in HIV-Infected Patients with Lipodystrophy
Landmark Phase III RCT. n=412 HIV lipodystrophy patients, tesamorelin 2 mg/day vs placebo, 26 weeks. CT-measured VAT: 15–18% reduction. Triglycerides significantly reduced. No change in fasting glucose, insulin sensitivity, or HbA1c — confirming intact feedback prevents insulin resistance. Basis for 2010 EGRIFTA® FDA approval. NEJM 2007;357(23):2349–2360. PMID: 18057338.
Cognitive Effects of Tesamorelin in HIV-Associated Lipodystrophy
Secondary analysis from Phase III trial. Tesamorelin patients preserved executive function and verbal memory vs. placebo decline. Effects correlated with IGF-1 levels — supporting IGF-1-mediated neuroprotection beyond metabolic endpoints. Research basis for GHRH axis modulation in cognitive aging models. NEJM 2012;366(15):1423–1424. PMID: 22490305.
Safety and Metabolic Effects of Tesamorelin in Patients with Type 2 Diabetes
12-week RCT in 53 T2D patients. Tesamorelin restored physiological GH and IGF-1 within normal range — even in metabolically vulnerable population — without inducing insulin resistance, worsening HbA1c, or altering OGTT. Confirms intact IGF-1 negative feedback prevents GH excess. Triglycerides reduced. PLOS One 2017;12(6):e0179538. PMC5472315.
EGRIFTA WR™ (Tesamorelin F8) — Full Prescribing Information
Most recent FDA prescribing info for EGRIFTA WR™ (F8, approved March 2025). Full molecular characterization: C₂₂₁H₃₆₆N₇₂O₆₇S, MW 5135.9 Da, 44-AA GHRH + trans-3-hexenoyl modification. PK: Tmax 0.15 hr, AUC 634.6 pg·h/mL. Complete Phase III efficacy, safety, contraindications. Authoritative reference for research-grade characterization. FDA accessdata NDA 022505.
Tesamorelin: GHRH Analogue Research, Mechanism & Metabolic Studies
2026 comprehensive review covering receptor binding through downstream metabolic effects. Detailed treatment of hexenoyl modification's basis for DPP-IV resistance and enhanced receptor binding. Covers pulsatile GH preservation, somatostatin feedback, and why IGF-1 feedback prevents excess. Reviews all Phase III data, body composition, cognitive, and lipid outcomes. March 2026.
Tesamorelin in HIV-Associated Lipodystrophy — Mechanism, Efficacy, Safety Review
Pharmacological review covering GHRH receptor pharmacology, AC/PKA/Ca²⁺ cascade, and pulsatile GH mechanism. All Phase II and III clinical data from the Theratechnologies program. Body composition outcomes, lipid effects, and metabolic safety profile. Analysis of pulsatile vs flat-line GH distinction for research applications. Pharmacological Research 2018.
Independent peer-reviewed research — not Trident Labs claims. Tesamorelin (research-grade) is not EGRIFTA®. Supplied for in vitro research use only. Not for human consumption.
References
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Effects of tesamorelin on cognitive function in HIV patients with abdominal fat accumulation
Safety and metabolic effects of tesamorelin in patients with type 2 diabetes
EGRIFTA WR™ Full Prescribing Information
Tesamorelin: GHRH Analogue Research, Mechanism of Action & Metabolic Studies
Tesamorelin binding kinetics and DPP-IV resistance — N-terminal hexenoyl modification
Support
Frequently Asked Questions
Everything you need to know about this product and your order.
